Home / Peptide guides / PT-141
Sexual health
PT-141 (bremelanotide, Vyleesi): benefits, results & how to take it
FDA-approved (as Vyleesi) Checked against official sources Oct 16, 2026
Quick facts
- What it is: a melanocortin-receptor drug that acts on desire in the brain.
- Status: FDA-approved as Vyleesi for premenopausal women with HSDD. Not for men or postmenopausal women.
- How it's taken: an as-needed autoinjector, at least 45 minutes before sex.
- Evidence: two Phase 3 randomized trials with 1,267 women.
- Most common side effects: nausea, flushing, injection-site reactions, headache, vomiting.
What is PT-141?
PT-141 is the old research code for bremelanotide. It acts on melanocortin receptors in the brain, which are involved in sexual desire. The approved product is Vyleesi, an autoinjector.
Is PT-141 FDA-approved?
FDA-approved (2019) as Vyleesi, only for premenopausal women with acquired, generalized low sexual desire (HSDD) that causes distress and isn't due to another condition, relationship problems, or a medicine. The label says it is not for postmenopausal women, men, or to enhance sexual performance (Vyleesi label). "PT-141" vials sold for research are not Vyleesi.
Vyleesi dosing & timing: what the FDA label says
Your prescriber sets your dose. This is a summary of the official FDA label to help you follow along, not a plan to start, change, or stop anything.
Vyleesi (autoinjector) — FDA label on DailyMed
- 1.75 mg injected under the skin of the abdomen or thigh, as needed, at least 45 minutes before expected sexual activity.
- No more than one dose in 24 hours.
- More than 8 doses a month is not recommended.
"PT-141" vials sold for research have no label. Their content isn't verified.
What the research shows
- RECONNECT trials (Obstet Gynecol, 2019): two 24-week randomized trials, 1,267 premenopausal women. Desire and distress scores improved modestly but significantly vs placebo. Nausea, flushing and headache hit 10%+ of users.
- Long-term extension (Obstet Gynecol, 2019): open-label follow-up of the same program.
New to these terms? See the glossary.
PT-141 FAQ
Is PT-141 FDA-approved?
Bremelanotide, the drug called PT-141 in research, is FDA-approved as Vyleesi for premenopausal women with acquired, generalized HSDD.
When do you take Vyleesi?
The label says at least 45 minutes before expected sexual activity, as needed, no more than once in 24 hours.
How many times a month can you use Vyleesi?
The label says more than 8 doses per month is not recommended.
Is PT-141 approved for men?
No. The Vyleesi label says it isn't indicated for men or to enhance sexual performance.
Not medical advice. Education only. We don't sell anything or tell you what to take. Label doses are there so you can follow along with your prescriber. Talk to a licensed clinician about your health.
All guides: Semaglutide · Tirzepatide · Retatrutide · Orforglipron (Foundayo) · BPC-157 · TB-500 (thymosin beta-4) · GHK-Cu (copper peptide) · Collagen peptides · Tesamorelin (Egrifta) · CJC-1295 & ipamorelin · MOTS-c · Semax · Peptides 101 · Why is peptide info so confusing?